Oxcarbazepine Tablet, Film Coated
Product Images NDC 60687-722

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 60687-722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150 mg Oxcarbazepine Tablet Blister (150 mg Blister)

150 mg Oxcarbazepine Tablet Blister (150 mg Blister)
This appears to be a list of prescription drug labels for a medication called Oxcarbazepine in the form of tablets. The tablets contain 150mg of the medication. The labels appear to have been printed with inconsistent formatting, including variations in capitalization and spacing, which may make it difficult to accurately identify the medication's instructions, warnings, or potential side effects.*
FDA Label Image

150 mg Oxcarbazepine Tablets Carton (150 mg Carton)

150 mg Oxcarbazepine Tablets Carton (150 mg Carton)
NDC 60687-711-01 is a medication containing Oxcarbazepine in tablet form. It comes in a bottle of 100 film-coated tablets, with each tablet containing 150mg of the active ingredient. The recommended dosage can be found on the packaging. The medication should be stored at room temperature between 20° and 25°C (68° and 77°F). This medication should be kept out of reach of children and not used if the seal is broken. It is distributed by American Health Packaging in Columbus, Ohio.*
FDA Label Image

300 mg Oxcarbazepine Tablet Blister (300 mg Blister)

FDA Label Image

300 mg Oxcarbazepine Tablets Carton (300 mg Carton)

300 mg Oxcarbazepine Tablets Carton (300 mg Carton)
Oxcarbazepine is a medicine available in the form of Tablets, USP, containing 100 tablets per pack. The tablets are film-coated and contain 600mg of Ghcarbazepine USP each. The usual dosage instructions can be found in the package insert. The medicine should be stored between 20-26°C (68-77°F) with excursions permitted between 15-30°C (59-86°F). It should be kept out of reach of children, and blister packs should not be used if they are torn or broken. The medicine is distributed by American Health Packaging, based in Columbus, Ohio. The National Drug Code (NDC) for this product is 60687-722-01. The accompanying Medication Guide should be given to each patient.*
FDA Label Image

600 mg Oxcarbazepine Tablet Blister (600 mg Blister)

FDA Label Image

600 mg Oxcarbazepine Tablets Carton (600 mg Carton)

600 mg Oxcarbazepine Tablets Carton (600 mg Carton)
This is a description of a medication called Oxcarbazepine which comes in the form of tablets. The tablets come in a bottle with 100 tablets which is an equivalent of 10 x 10 packs. The suggested dosage is contained in the package insert. It should be stored at the temperature between 15°C to 30°C. The medication is to be kept out of reach of children and not to be used if the blister is torn or broken. The name of the manufacturer is Camber Pharmaceuticals, Inc. The medication is distributed by American Health Packaging. The NDC code for the medication is 60687-733-01.*
FDA Label Image

Ahp71101

FDA Label Image

Ahp72201

FDA Label Image

Ahp73301

FDA Label Image

Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure1)

Figure 1: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure1)
The log-rank test was performed with a p-value of 0.0001. The table shows the time on trial from Day 2 to Day 11 for the Oxcarbarspine treatment group.*
FDA Label Image

Figure 2: Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group (Figure2)

FDA Label Image

Figure 3: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure3)

Figure 3: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure3)
The given text provides the result of the log-rank test which is a statistical hypothesis test to compare the survival distributions of two groups. The p-value mentioned is 0.0001 which suggests that there is a significant difference between the groups being compared. The rest of the text seems to be an unrelated gibberish due to errors.*
FDA Label Image

Figure 4: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure4)

Figure 4: Kaplan-meier Estimates Of Exit Rate By Treatment Group (Figure4)
This is a statistical output from a log-rank test showing the p-value to be 0.0001. The rest of the text is not clear but seems to refer to a study or experiment involving a group receiving some sort of treatment which is labeled "HIGH" and "LOW". The x-axis shows a time scale up to 130 days.*
FDA Label Image

Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.